Clinical trials: Anticoagulant Drugs
Thrombin-specific Anticoagulant Bivalirudin During Percutaneous Coronary Intervention (PCI)
ImproveR International (BI-001-IM)
The objectives of this registry are to assess the use of the thrombin-specific anticoagulant bivalirudin during percutaneous coronary intervention (PCI) in a real life setting.
- Trial name
- NCT00290849
- Testing
- Bivalirudin
- Where
- Denmark
- Volunteers
- 4,000 people
- Sponsor
- Nycomed
Healthy Volunteers
A Study in Healthy Participants Investigating Biomarkers After Exposure to Heparin When Heparin is Administered in the Fasted State or After a High-fat Meal. Heparin, a Registered Drug, is an Anticoagulant (Blood Thinner) That Prevents the Formation of Blood Clots.
In this study biomarkers in the blood after exposure to heparin in the fasted state or after a high-fat meal will be investigated.
- Trial name
- NCT05178550
- Testing
- Heparin
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Pulmonary Embolism, Venous Thrombosis
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
PEPPER is a randomized study comparing the three most commonly used anticoagulants in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery.
- Trial name
- PEPPER (NCT02810704)
- Testing
- Enteric Coated Aspirin, Warfarin, Rivaroxaban
- Where
- 32 sites in United States, Canada
- Volunteers
- 18,883 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Venous Thromboembolism
Risk of Recurrent Venous Thrombosis: A Validation Study of the Vienna Prediction Model
Because of a high recurrence risk after unprovoked venous thromboembolism (VTE) indefinite anticoagulation is recommended, but confers a considerable bleeding risk.
- Trial name
- NCT01972243
- Testing
- no intervention
- Where
- Austria
- Volunteers
- 800 people
- Sponsor
- Medical University of Vienna
Thrombosis
Pharmacogentic Screening of Coumarine Based Oral Anticoagulant Using Next Generation Seguencer
As drug response is a complex trait in the majority of cases using an optimal starting dose for an individual may reduce the time taken to reach a stable INR, and reduce the risk of having either a high INR (with a risk of…
- Trial name
- NCT03180567
- Testing
- Genetic Mutations
- Where
- Egypt
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tanta University
Anticoagulants
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Single-institution uncontrolled open-label trial.
- Trial name
- NCT05319340
- Testing
- prescribing anticoagulant therapy
- Volunteers
- 1,000 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Bleeding Complications
Clopidogrel Monotherapy in Patients With High Bleeding Risk
The goal of this research is to show that a shorter duration of two antiplatelet medications (compared to the standard of care) is safe and effective while reducing the risk of bleeding complications.
- Trial name
- NCT05223335
- Testing
- Clopidogrel, Prasugrel, Tricagrelor
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Mayo Clinic
Pulmonary Embolism Acute
Evaluation of the Standard Catheter-directed Thrombolysis Effectiveness in Intermediate-High-Risk Pulmonary Embolism Patients
A single-center, open-label, randomized comparative study of two treatment strategies in patients with intermediate-high-risk acute pulmonary embolism (PE).
- Trial name
- ESCADlys-PE (NCT06487052)
- Testing
- Standard Catheter-Directed Low Dose Thrombolysis, Standard Anticoagulation
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Valvular Heart Disease
RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial
RIvaroxaban for Valvular heart diseasE and atRial fibrillation trial (RIVER trial).
- Trial name
- NCT02303795
- Testing
- Rivaroxaban, Warfarin
- Where
- Brazil
- Volunteers
- 1,005 people
- Sponsor
- Hospital do Coracao
Atrial Fibrillation
Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
1. The recent development of novel oral anticoagulants (NOACs), including direct thrombin inhibitor (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), could potentially overcome many drawbacks of…
- Trial name
- DARING-AF (NCT02666157)
- Testing
- Dabigatran etexilate, Rivaroxaban, Apixaban
- Where
- 5 sites in Taiwan
- Volunteers
- 3,672 people
- Sponsor
- National Cheng-Kung University Hospital
Adherence to Personalized EBM Anticoagulant Treatment in Patients at High Risk for Stroke
Personalized Evidence-based Medicine in Patients With Atrial Fibrillation
A retrospective analysis
- Trial name
- NCT04774341
- Testing
- anticoagulation treatment
- Where
- Russia
- Volunteers
- 4,200 people
- Sponsor
- Center of Personalized Medicine, Pirogova
Thrombosis, Venous
The Impact of MTM Model on the Efficacy and Safety of Anticoagulant Therapy in Postoperative Colorectal Cancer Patients
Anticoagulants are classified as high-risk medications, with their main adverse drug events (ADEs) being recurrent venous thromboembolism (VTE) and bleeding events.Postoperative colorectal cancer (CRC) patients exhibit a high…
- Trial name
- NCT06998745
- Testing
- Medication Therapy Management (MTM) model
- Where
- China
- Volunteers
- 327 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Coronary Artery Disease
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Clopidogrel is the P2Y12 inhibitor of choice in PCI patients requiring OAC. However, concerns have been raised based on the notion that a considerable number of patients may have inadequate response to clopidogrel.
- Trial name
- SWAP-AC-2 (NCT04483583)
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Florida
Anticoagulant Reversal, Reversal of Edoxaban Induced Anticoagulation
Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban
PER977 monotherapy and co-administration following 60 mg edoxaban will have an acceptable safety and tolerability profile with no impact on pro-coagulant biomarkers.
- Trial name
- PER977-P1 (NCT01826266)
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Pulmonary Embolism
Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04879407
- Testing
- Rivaroxaban, Warfarin
- Where
- United States
- Volunteers
- 98,947 people
- Sponsor
- Brigham and Women's Hospital
Atrial Fibrillation
Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban
Evaluation of the performance of the 2MACE index in a population of nonvalvular atrial fibrillation (NVAF) patients treated with rivaroxaban in Spain
- Trial name
- EMIR (NCT02975453)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Spain
- Volunteers
- 1,481 people
- Sponsor
- Bayer
Non-Valvular Atrial Fibrillation (NVAF)
A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan
The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.
- Trial name
- NCT05027061
- Where
- Japan
- Volunteers
- 11,776 people
- Sponsor
- Bristol-Myers Squibb
Liver Cirrhosis, Portal Vein Thrombosis
Clinical Application of Simcyp-Guided Warfarin Initiation Doses in Cirrhotic Patients With Portal Vein Thrombosis
This was a prospective, open-label, pilot interventional clinical study conducted on Egyptian patients with liver cirrhosis complicated by portal vein thrombosis (PVT) who were indicated for anticoagulation therapy.
- Trial name
- NCT07571460
- Testing
- Warfarin 3 mg, Warfarin 2 mg
- Where
- Egypt
- Volunteers
- 21 people
- Sponsor
- Kafrelsheikh University
Chronic Kidney Failure, Vascular Graft Occlusion
A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis
The study will look at the safety profile (unwanted effects) of the long-lasting anticoagulant PEG-hirudin (SPP200) and compare these unwanted effects to those of unfractionated heparin, commonly used in haemodialysis to avoid…
- Trial name
- NCT00074620
- Testing
- PEG-hirudin
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Speedel Pharma Ltd.
Coagulation Disorders
Evaulation of Interaction Between Herbal Products and Anticoagulants
The purpose of this study is to determine if the use of herbal products interferes with normal anticoagulation, leading to either excessive thinning of the blood and bleeding problems or inadequate thinning of the blood and…
- Trial name
- NCT00071682
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Francisco